Navigation Links
VIVUS to Present at the BioCentury NewsMakers Conference
Date:10/14/2011

MOUNTAIN VIEW, Calif., Oct. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference.

The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Friday, October 21, 2011 at 10:00 a.m. ET.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com 650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. VIVUS to Participate in Three Investor Conferences in September
2. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
3. VIVUS Reports First Quarter 2011 Financial Results
4. VIVUS to Present at Four Upcoming Investor Conferences in May
5. VIVUS to Present at the 10th Annual Needham Healthcare Conference
6. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
7. VIVUS to Present at Four Upcoming Investor Conferences
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
10. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
11. VIVUS to Present at Four Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... , , ... genome variations, development of sequencing technologies, and their applications. Current ... developing them. Various applications of sequencing are described including those ...
(Date:12/4/2016)... Francisco, CA (PRWEB) , ... December 03, 2016 ... ... grants to ground-breaking microbiome studies. A microbiome impact grant award has been made ... the effect of heavy smoking and drinking on the oral microbiome. Grant proposals ...
(Date:12/2/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will ... Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE mark ...
(Date:12/2/2016)... 2016 Amgen (NASDAQ: AMGN ) and ... submission of a Marketing Authorization Application (MAA) to the European ... Avastin ® (bevacizumab). The companies believe this submission is ... "The submission of ABP 215 to the EMA ... oncology portfolio," said Sean E. Harper , M.D., executive ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):